Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
DNA replication inhibitor
DRUG CLASS:
DNA replication inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
PVEK (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
inotuzumab ozogamicin (28)
gemtuzumab ozogamicin (24)
idarubicin (22)
bendamustine (12)
loncastuximab tesirine-lpyl (7)
trastuzumab duocarmazine (6)
MEDI7247 (6)
ABBV-321 (6)
rovalpituzumab tesirine (5)
SGN-CD19B (5)
SOT102 (5)
MGC018 (5)
PVEK (4)
IMGN779 (3)
ADCT-301 (3)
BYON3521 (2)
CS5001 (2)
IKS03 (2)
ITC-6102RO (2)
NBE-002 (2)
SGN-CD123A (2)
SGN-CD352A (2)
TR1801-ADC (2)
ADCT-601 (2)
SGN-CD33A (2)
ADCT-211 (1)
ADCT-212 (1)
ADCT-701 (1)
DHES0815A (1)
MEDI3726 (1)
SGN-CD70A (1)
SC-003 (1)
ADCT-502 (0)
MDX-1203 (0)
MEDI2228 (0)
nimorazole (0)
PF-06647263 (0)
SC-006 (0)
SC-007 (0)
SYD1875 (0)
ADCT-602 (0)
›
Associations
(168)
News
Trials
VERI cancer hierarchy
Reset Filters
CD33 positive
Acute Myelogenous Leukemia
CD33 positive
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
gemtuzumab ozogamicin
Sensitive: A1 - Approval
gemtuzumab ozogamicin
Sensitive
:
A1
CD22 positive
B Acute Lymphoblastic Leukemia
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: A1 - Approval
loncastuximab tesirine-lpyl
Sensitive
:
A1
loncastuximab tesirine-lpyl
Sensitive: A1 - Approval
loncastuximab tesirine-lpyl
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
inotuzumab ozogamicin
Sensitive: A1 - Approval
inotuzumab ozogamicin
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
bendamustine
Sensitive: A1 - Approval
bendamustine
Sensitive
:
A1
bendamustine
Sensitive: A1 - Approval
bendamustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
bendamustine
Sensitive: A1 - Approval
bendamustine
Sensitive
:
A1
bendamustine
Sensitive: A1 - Approval
bendamustine
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
carboplatin + etoposide oral + bendamustine
Sensitive: A2 - Guideline
carboplatin + etoposide oral + bendamustine
Sensitive
:
A2
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
CD20 inhibitor + bendamustine
Sensitive: A2 - Guideline
CD20 inhibitor + bendamustine
Sensitive
:
A2
CD20 inhibitor + bendamustine
Sensitive: A2 - Guideline
CD20 inhibitor + bendamustine
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
inotuzumab ozogamicin
Sensitive: A2 - Guideline
inotuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
RUNX1-RUNX1T1 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
CBFB-MYH11 fusion
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Acute Promyelocytic Leukemia
No biomarker
Acute Promyelocytic Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
gemtuzumab ozogamicin
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
blinatumomab + inotuzumab ozogamicin
Sensitive: A2 - Guideline
blinatumomab + inotuzumab ozogamicin
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab duocarmazine
Sensitive: B - Late Trials
trastuzumab duocarmazine
Sensitive
:
B
trastuzumab duocarmazine
Sensitive: B - Late Trials
trastuzumab duocarmazine
Sensitive
:
B
DLL3 overexpression
Small Cell Lung Cancer
DLL3 overexpression
Small Cell Lung Cancer
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
rovalpituzumab tesirine
Sensitive: B - Late Trials
rovalpituzumab tesirine
Sensitive
:
B
CD123 positive
Acute Myelogenous Leukemia
CD123 positive
Acute Myelogenous Leukemia
PVEK
Sensitive: C2 – Inclusion Criteria
PVEK
Sensitive
:
C2
PVEK
Sensitive: C2 – Inclusion Criteria
PVEK
Sensitive
:
C2
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
BCR-ABL1 fusion
Acute Lymphocytic Leukemia
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
bosutinib + inotuzumab ozogamicin
Sensitive: C2 – Inclusion Criteria
bosutinib + inotuzumab ozogamicin
Sensitive
:
C2
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
capecitabine + bendamustine
Sensitive: C2 – Inclusion Criteria
capecitabine + bendamustine
Sensitive
:
C2
capecitabine + bendamustine
Sensitive: C2 – Inclusion Criteria
capecitabine + bendamustine
Sensitive
:
C2
CD123 positive
Acute Myelogenous Leukemia
CD123 positive
Acute Myelogenous Leukemia
venetoclax + PVEK
Sensitive: C2 – Inclusion Criteria
venetoclax + PVEK
Sensitive
:
C2
venetoclax + PVEK
Sensitive: C2 – Inclusion Criteria
venetoclax + PVEK
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login